Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
CBIO Stock Chart & Stats
$12.54
--
Market closed
$12.54
--
Day’s Range― - ―
52-Week Range$9.81 - $63.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)146.16K
Market Cap
$171.57M
Enterprise Value$7.94M
Total Cash (Recent Filing)$152.65M
Total Debt (Recent Filing)$1.64M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Apr 30, 2026EPS EstimateN/A
Last Dividend Ex-Date
Jan 13, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding13,892,562
10 Day Avg. Volume161,911
30 Day Avg. Volume146,159
Financial Highlights & Ratios
PEG Ratio-24.58
Price to Book (P/B)-139.86
Price to Sales (P/S)0.00
P/FCF Ratio-51.61
Enterprise Value/Market Cap0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$25.60Price Target Upside104.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical PotentialPreclinical studies show that CR-001 demonstrates VEGF-dependent cooperative PD-1 binding activity, making it a promising candidate.
Market PositioningCrescent is well-positioned to take advantage of the PD-1 x VEGF market as both a fast-follower in large indications and potentially first-to-market in smaller validated indications.
Strategic AdvantageCBIO's internal ADC portfolio and US-only studies could help close the gap and provide an edge over competitors.
Valuation And M&A PotentialCrescent Biopharma is viewed as having an attractive valuation and being a potential M&A target, which can positively influence its stock performance.
Bears Say
Competitive PositionThere are questions about the PD-1xVEGF class, and CR-001 is behind other PD-(L)1×VEGFs that are in later stages of clinical development.
Market CompetitionCR-001 is designed as a fast-follower to a successful competitor drug, suggesting potential for similar clinical success.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $9.81 and its highest was $63.00 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $171.57M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Apr 30, 2026 which is in 193 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on May 01, 2025. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 13,892,562 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went up 4.493%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
Crescent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.60 (104.15% Upside)
$25.60 (104.15% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.88%
12-Months-Change
Fundamentals
Return on Equity
-51.70%
Trailing 12-Months
Asset Growth
544.72%
Trailing 12-Months
Company Description
Crescent Biopharma
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$25.60
▲(104.15% Upside)
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Akari Therapeutics
―
BioVie
―
Capstone Therapeutics
―
Allarity Therapeutics
―
Ownership Overview
0.45% Insiders
19.15% Mutual Funds
― Other Institutional Investors
80.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---